Develops immunotherapy products for the treatment of cancer and infectious diseases.
CEL-SCI Corporation, headquartered in Vienna, Virginia, is a pioneering clinical-stage biotechnology company dedicated to advancing immune-based therapies for cancer and infectious diseases. At the forefront of its research is Multikine, an investigational immunotherapy designed to activate the immune system against locally advanced primary squamous cell carcinoma of the head and neck. This therapy has completed pivotal Phase 3 clinical trials, marking a significant milestone in the company's efforts to address critical medical needs.
In addition to Multikine, CEL-SCI is pioneering the Ligand Epitope Antigen Presentation System (LEAPS) technology. This innovative approach, currently in pre-clinical stages, stimulates the human immune system to combat a wide range of conditions, including bacterial, viral, and parasitic infections, autoimmune diseases, allergies, transplantation rejections, and cancer. The company's robust pipeline also includes CEL-2000 and CEL-4000 product candidates, aimed at advancing therapeutic options for rheumatoid arthritis.
Established in 1983, CEL-SCI continues to drive innovation in biotechnology, leveraging its expertise to develop transformative treatments that harness the power of the immune system. With a commitment to improving patient outcomes and addressing unmet medical needs, CEL-SCI Corporation remains dedicated to advancing the frontier of immunotherapy and immune modulation technologies.